Prostate cancer genetic testing — the germline and somatic molecular profiling enabling treatment selection, hereditary risk assessment, clinical trial eligibility, and prognostic stratification — creates the companion diagnostic commercial market, with the Prostate Cancer Market reflecting precision oncology testing as an increasingly important commercial market dimension.

Germline genetic testing in prostate cancer — the BRCA1/2, ATM, CDK12, PALB2, MSH2/6, and other hereditary cancer gene testing recommended for all metastatic prostate cancer patients and high-risk localized patients per NCCN guidelines — creates the germline testing market. The eleven to twelve percent of metastatic prostate cancer patients carrying germline mutations (predominantly BRCA2) with treatment and familial implications creating the clinical rationale for routine germline testing.

Comprehensive genomic profiling for treatment selection — the FoundationOne CDx, Caris Molecular Intelligence, Tempus xF, and Guardant360 tissue and liquid biopsy platforms providing actionable genomic information for PARP inhibitor eligibility, MSI-H pembrolizumab eligibility, and clinical trial enrollment — represent the somatic profiling commercial market. The FDA-approved FoundationOne CDx as companion diagnostic for olaparib in HRR-mutated mCRPC creating the regulatory anchor for comprehensive genomic profiling.

AR-V7 testing — the CTC (circulating tumor cell)-based AR splice variant 7 (AR-V7) detection test (Oncobiologics Epic Sciences test) predicting primary resistance to enzalutamide and abiraterone and guiding toward chemotherapy — represents the treatment selection molecular test specific to mCRPC clinical decision-making.

Do you think prostate cancer genetic testing will achieve universal adoption across all prostate cancer stages, or will cost and actionability limitations maintain germline testing primarily in the metastatic setting?

FAQ

Which genes are tested for prostate cancer and why? Germline testing indications: BRCA1/2 (high prevalence, PARP inhibitor eligibility, familial cancer syndrome); ATM (PARP inhibitor some benefit); CDK12 (immune checkpoint inhibitor potential); PALB2 (BRCA2-like behavior); MLH1, MSH2, MSH6, PMS2 (Lynch syndrome, MSI-H — pembrolizumab eligibility); HOXB13 (familial risk); NCCN recommends germline testing for: all metastatic prostate cancer; regional disease with Gleason group 4-5 or multiple family history factors; any grade with Ashkenazi Jewish ancestry; approximately eleven to twelve percent metastatic prostate cancer patients have germline mutation.

What is the clinical significance of MSI-H in prostate cancer? MSI-H (microsatellite instability-high) prostate cancer: approximately three percent of mCRPC patients; Lynch syndrome associated (BRCA2 or MMR gene mutations); highly immunogenic from mutation burden; pembrolizumab (Keytruda) approved for any MSI-H solid tumor (tumor-agnostic approval); MSI-H testing: IHC for MMR proteins (MLH1, MSH2, MSH6, PMS2) or PCR-based MSI testing; FoundationOne CDx and other CGP platforms; pembrolizumab response rate approximately thirty to fifty percent in MSI-H prostate cancer; rare but actionable biomarker with durable response potential.

#ProstateCancer #ProstateCancerGenetics #BRCA #GermlineProstate #PrecisionProstate #CompanionDiagnostic